BIOPOR Stock Overview
An in-vitro diagnostics company, provides biomarker tools and antibodies for clinical research in Europe, North America, Asia, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
My Notes
Capture your thoughts, links and company narrative
BioPorto A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | DKK 1.49 |
| 52 Week High | DKK 2.85 |
| 52 Week Low | DKK 1.21 |
| Beta | 1.17 |
| 1 Month Change | -7.80% |
| 3 Month Change | -19.72% |
| 1 Year Change | -27.32% |
| 3 Year Change | -39.68% |
| 5 Year Change | -49.92% |
| Change since IPO | -99.35% |
Recent News & Updates
Recent updates
We're Hopeful That BioPorto (CPH:BIOPOR) Will Use Its Cash Wisely
Oct 22
We Think BioPorto (CPH:BIOPOR) Needs To Drive Business Growth Carefully
Dec 25We Think BioPorto (CPH:BIOPOR) Needs To Drive Business Growth Carefully
Jun 28We're Hopeful That BioPorto (CPH:BIOPOR) Will Use Its Cash Wisely
Feb 27Companies Like BioPorto (CPH:BIOPOR) Are In A Position To Invest In Growth
Oct 19We're Keeping An Eye On BioPorto's (CPH:BIOPOR) Cash Burn Rate
Jun 15Is BioPorto (CPH:BIOPOR) In A Good Position To Deliver On Growth Plans?
Feb 17Here's Why We're Not Too Worried About BioPorto's (CPH:BIOPOR) Cash Burn Situation
Oct 16Companies Like BioPorto (CPH:BIOPOR) Are In A Position To Invest In Growth
May 28BioPorto A/S' (CPH:BIOPOR) Path To Profitability
Mar 01We Think BioPorto (CPH:BIOPOR) Needs To Drive Business Growth Carefully
Jan 24A Look At BioPorto's (CPH:BIOPOR) CEO Remuneration
Dec 20The BioPorto A/S (CPH:BIOPOR) Analysts Have Been Trimming Their Sales Forecasts
Nov 23
BioPorto A/S (CPH:BIOPOR) Analysts Are Cutting Their Estimates: Here's What You Need To Know
Nov 21Shareholder Returns
| BIOPOR | DK Biotechs | DK Market | |
|---|---|---|---|
| 7D | -6.4% | -0.6% | -9.0% |
| 1Y | -27.3% | -10.3% | -5.3% |
Return vs Industry: BIOPOR underperformed the Danish Biotechs industry which returned -8.9% over the past year.
Return vs Market: BIOPOR underperformed the Danish Market which returned -4.9% over the past year.
Price Volatility
| BIOPOR volatility | |
|---|---|
| BIOPOR Average Weekly Movement | 6.6% |
| Biotechs Industry Average Movement | 7.5% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in DK Market | 10.2% |
| 10% least volatile stocks in DK Market | 2.8% |
Stable Share Price: BIOPOR's share price has been volatile over the past 3 months compared to the Danish market.
Volatility Over Time: BIOPOR's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of Danish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1917 | 36 | Peter Eriksen | bioporto.com |
BioPorto A/S, an in-vitro diagnostics company, provides biomarker tools and antibodies for clinical research in Europe, North America, Asia, and internationally. It offers the neutrophil gelatinase-associated lipocalin test, a quantitative particle-enhanced turbidimetric immunoassay designed to run on automated clinical chemistry analyzers; monoclonal antibodies for scientific, pharmaceutical, and clinical research; and enzyme-linked immunosorbent assay kits, as well as generic rapid assay device for custom lateral flow assays. BioPorto A/S was incorporated in 1917 and is based in Hellerup, Denmark.
BioPorto A/S Fundamentals Summary
| BIOPOR fundamental statistics | |
|---|---|
| Market cap | DKK 640.19m |
| Earnings (TTM) | -DKK 61.30m |
| Revenue (TTM) | DKK 34.91m |
18.3x
P/S Ratio-10.4x
P/E RatioIs BIOPOR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BIOPOR income statement (TTM) | |
|---|---|
| Revenue | DKK 34.91m |
| Cost of Revenue | DKK 10.05m |
| Gross Profit | DKK 24.86m |
| Other Expenses | DKK 86.16m |
| Earnings | -DKK 61.30m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Mar 20, 2025
| Earnings per share (EPS) | -0.14 |
| Gross Margin | 71.22% |
| Net Profit Margin | -175.62% |
| Debt/Equity Ratio | 0% |
How did BIOPOR perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 09:26 |
| End of Day Share Price | 2024/12/23 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
BioPorto A/S is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | Brookline Capital Markets |
| Jyoti Prakash | Edison Investment Research |
| Yi Chen | H.C. Wainwright & Co. |